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Abstract
Background: We investigated the relationship between myometrial invasion and the prognostic factors on overall and progres-
sion free survival in endometrial carcinoma.
Methods: 122 cases operated with endometrial cancer were included into the study. Progression-free survival and overall surviv-
al were evaluated according to degree of  myometrial invasion. We also investigated the relationship between myometrial invasion 
and prognostic factors. 
Results: The 5- year progression-free survival rate was 90 % in stage I, 66 % in stage II, 32 % in stage III and 60 % in stage IV. 
The 5- year overall survival rate was 95 % in stage I, 89 % in stage II, 49 % in stage III and 30 % in stage IV. The progression 
free survival and overall survival for patients with more than 50 % myometrial invasion were detected 67 % at 58 months and 
66 % at 60 months, respectively. The clinicopathological variables that significantly correlated with myometrial invasion of  more 
than 50 % were as follows: pelvic lymph node metastasis (p: 0,00029-OR: 11.2), cervical stromal invasion (p: 0008-OR:7.9), LVSI 
(p< 0.0001-OR: 16.5).
Conclusion: The depth of  myometrial invasion is one of  the most important prognostic indicators and determinants of  therapy 
in endometrial cancer. 
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Introduction
Endometrial cancer affects mainly postmenopausal wom-
en. The average age of  women diagnosed with endome-
trial cancer is 60. It is uncommon in women under the 
age of  45. In 2018, it is estimated that there will be 63,230 
new cases of  uterine cancer and an estimated 11,350 peo-
ple will die of  this disease1. These estimates include both 
endometrial cancers and uterine sarcomas. About 63,230 
new cases of  cancer of  the uterine corpus will be diag-
nosed, but only about 5,058 of  these cases will be uterine 
sarcomas. Up to 8% of  uterine corpus cancers are sarco-
mas, so the actual numbers for endometrial cancer cases 
and deaths are slightly lower than these estimates2. For-
tunately, the majority of  women with endometrial cancer 
are diagnosed at an early stage (the disease is confined 
to the uterine corpus) and may be cured by surgery with 
or without adjuvant radiotherapy3. Survival is obviously 
stage related. According to a study by Creasman; the 5- 
year progression-free survival rate was 92 % in stage I, 82 
% in stage II, 68 % in stage III and 29 % in stage IV4. 
The 5- year overall survival rate was 89 % in stage I, 78 % 
in stage II, 61 % in stage III and 21 % in stage IV4.
In endometrial carcinoma, myometrial invasion is a well-
known predictor of  recurrence, and important in the de-
cision making for adjuvant treatment5.
The objective of  this study was to analyze the effect of  
myometrial invasion on overall and progression free sur-
vival in endometrial carcinoma. The relationship between 
myometrial invasion and other known prognostic factors 
in endometrial cancer was also studied.
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Material and methods
We reviewed the records of  122 endometrial carcino-
ma patients treated at University of  Health Sciences, 
Haseki Training and Research Hospital, Department of  
Gynecology and Obstetrics, Division of  Gynecologic 
Oncology. Ethics Committee Approval was taken from 
the local committee of  our institution. All patients un-
derwent staging procedures including total hysterectomy, 
adnexectomy, peritoneal washings for cytology, pelvic 
and para-aortic lymphadenectomy, and omentectomy if  
indicated. All cases were histologically confirmed as en-
dometrioid adenocarcinoma, papillary serous carcinma, 
clear cell carcinoma, or carcinosarcoma, and were includ-
ed in the study. All cases of  endometrial stromal sarco-
ma and leiomyosarcoma were excluded. Progression-free 
survival (PFS) was defined as the period between the time 
of  surgery and the observation of  the recurrence. Over-
all survival (OS) was the time between the surgery and 
death, and follow-up time was evaluated as the time be-
tween the surgery and the time that the patient was last 
examined (death or last visit).  
Statistical analysis
Data were analyzed using SPSS statistical software, ver-
sion 11.5. Descriptive statistics were used to analyze de-
mographic data and were summarized as numbers with 
percentage or median with range. Progression free sur-
vival (PFS), overall survival (OS) were analyzed by the 
Kaplan-Meier method. Comparisons of  survival curves 
were performed using the log-rank test. The effect of  
myometrial invasion was analyzed taking into account 
other variables significantly linked to survival. Odds ra-
tios and 95 % confidential intervals were used to assess 
the risk of  myometrial invasion in relation to each patho-
logical variable. P-values of  <0.05 were considered sig-
nificant.  
 
Results
A total of  122 patients with endometrial cancer under-
went primary surgery at our institution. The average age 
of  patients was 58.5 ± 10 years (median 58; range 32 - 86 
years. All the patients underwent abdominal hysterectomy 
and bilateral salpingo-oophorectomy (BSO). 109 patients 
underwent a hysterectomy and bilateral salpingo-oopho-
rectomy with pelvic lymphadenectomy. Pelvic and/or pa-
ra-aortic lymphadenectomy was performed in 19 patients. 
Omentectomy was performed in 102 patients. Intraop-
erative peritoneal cytology was performed in 122 pa-
tients. At the time of  diagnosis, 26 patients (14.8 %) were 
pre-menopausal, and 96 (85.2 %) were postmenopausal. 
Patient’s characteristics
Endometriod adenocarcinoma was the most common 
histological form of  endometrial cancer. Histologically, 
while 112 (91.8 %) patients were endometrioid, the re-
maining 10 (8.1 %) had non-endometrioid histology. His-
tological grades were as follows: 59 (48.3 %) grade 1, 38 
(31.1 %) grade 2, and 25 (20.4 %) grade 3. The distribu-
tion of  surgical FIGO stages were 77 (63.1 %) Stage Ia, 
21 (17.2 %) Stage Ib, 8 (6.5 %) Stage II, 1 (0.8 %) Stage 
IIIa, 1 (0.8 %) Stage IIIb, 7 (5.7 %) Stage IIIc1, 2 (1.6 %) 
Stage IIIc2, 1 (0.8 %) Stage IVa, and 4 (3.2 %) Stage IVb. 
Myometrial invasion was documented in 97 cases (79.5 
%). Myometrial invasion was found 74.4 % in stage I cas-
es. Adnexal spread was detected in 5.7 %, it’s was found 2 
cases in stage 3 and all cases in stage 4. Cervical involve-
ment was seen in 18 % of  the patients. These patients are 
evaluated as separate 4 % in stage I and 6.5 % in stage II, 
Stage III and Stage IV at 4 %, 3.2%, respectively. Lym-
phovascular space invasion was detected in 32 (26.2 %) 
cases. LVSI evaluation of  our patients when the absence 
of  invasion in 90 patients (73.7 %) 32 patients were found 
to be in the invasion (26.2 %). When analyzed LVSI ac-
cording to the stage 12.2 % in stage I, 50 % in stage II, 
100 % in Stage III and Stage IV. Of  the 122 subjects, 9 
patients (7.4 %) had positive peritoneal cytology and 113 
(92.6 %) had negative cytology. Four of  them were in 
stage I, 1 in stage II, in 1 case in stage III and in stage IV 
in 3 cases. Omental metastases were found in 4 (3.9 %) 
of  102 patients.
African Health Sciences Vol 19 Issue 4, December, 2019 3236
Table 1- The relationship between >50 % myometrial invasion – prognostic factors 
  
Parameters 
  
Odds ratios 
  
95 % Confidential 
intervals 
  
P values 
Myometrial Invasion-
Pelvic Lymph Node 
Involvement 
11.2 2,2-55,3 0,00029 
Myometrial Invasion –
Cervical Stromal 
Involvement 
7.9 2,3-26,6 0,0008 
Myometrial Invasion –
Omental Involvement 
16.8 0,8-321,7 0,06* 
Myometrial Invasion –
Lympho Vascular Space 
Involvement 
16.5 6,09-44,7 0,0001 
Myometrial Invasion –
Adnexal spread 
35.4 1,9-637,7 0,001 
Myometrial Invasion – 
Peritoneal cytology 
16.4 1,9-139,0 0,01 
               *P>0.05 insignificantly. 
Pelvic lymph node dissection was performed on a hun-
dred-nine patients and both pelvic and para-aortic lymph 
node dissection was performed on nineteen patients. In 
total, 14 patients (11.4 %) had lymph node metastases. 
Eleven patients (n: 11/109, 10 %) had metastasis in the 
pelvic region, and three patients (n: 3/19, 15.7 %) had 
tumor in the para-aortic region. Seventeen patients (13.9 
%) developed recurrences.
Recurrences
The recurrence was detected 17 patients. Recurrence was 
outside of  the pelvic region in 6 patients. The recurrence 
site was vaginal in 11 patients (64.7 %), abdominal skin in 
1 patient (5.8 %), liver in 3 patients (17.6 %), and small 
intestine in 2 patients (11.7 %). The recurrence rate was 
detected 37.5 % excluded Stage Ia cases. 77 patients were 
not included in the analysis because of  Stage Ia.
Survival analysis
Kaplan-Meier survival analysis was performed in the 
evaluation of  122 patients. The 5-year PFS of  the pa-
tients according to stage of  the disease was: 90 % in stage 
I, 66 % in stage II, 32 % in stage III and 60 % in stage IV. 
Between the survival curves were significantly difference 
in Kaplan-Meier analysis (p<0,0001). The OS of  the pa-
tients according to stage of  the disease was: 95 % in stage 
I, 89 % in stage II, 49 % in stage III and 39 % in stage IV. 
Between the survival curves were significantly difference 
in Kaplan-Meier analysis (p<0,0001) (Figure 1).
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        Figure 1- Progression-free survival and overall survival in the study population. 
The 5-year PFS rate for patients with myometrial invasion 
< 50% was 88 % compared 67 % for the patients with 
myometrial invasion > 50 % (p: 0,0013). The 5-year OS 
rate was 96 % for patients with myometrial invasion < 50 
% versus 66 % for those with myometrial invasion > 50 
% (p< 0,0001).  Between the survival curves were signifi-
cantly difference in Kaplan-Meier analysis both PFS and 
OS (Figure 2).
 
     Figure 2- Progression-free survival and overall survival at >50% myometrial invasion. 
The relationship between myometrial invasion – 
prognostic factors
When patients with myometrial invasion of  more than 50 
%, pelvic lymph node metastasis, cervical involvement, 
LVSI, adnexal spread, peritoneal cytology positivity, and 
omental involvement were analyzed (Table-1). Statisti-
cally significant associations were found between deep 
myometrial invasion and cervical stromal invasion (OR: 
7,9- 95% CI: 2,3-26,6- p: 0,0008), positive peritoneal fluid 
cytology (OR: 16,4-95% CI: 1,9-139,0-p: 0,01), adnex-
al spread (OR: 35,4-95% CI: 1,9-637,7-p: 0,001), LVSI 
(OR: 16,5-95% CI: 6,09- 44,7-p<0,0001), and pelvic 
lymph node involvement (OR: 11.2-95% CI: 2.2-55,3-p: 
0,00029). No association was found between myometrial 
invasion and the omental metastases (OR: 16,8-95% CI: 
0,8-321,7-p: 0,06).
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Discussion
In this study, we evaluated the relationship between myo-
metrial invasion and prognostic factors- survival analysis. 
Myometrial invasion was documented in 97 cases (79.5 
%). Myometrial invasion was found 74.4 % in stage I cas-
es. In the present study, the progression free survival and 
overall survival for patients with more than 50 % myome-
trial invasion were detected 67 % and 66 %, respectively.
Recently, screening of  biological indexes and gene thera-
pies for endometrial carcinoma is becoming an active re-
search field. Specific indicators of  adverse outcomes are 
needed in order to tailor the management of  endome-
trial cancer and improve their survival rates. During the 
last decades microcystic, elongated, fragmented (MELF) 
histologic pattern has been examined and proposed as a 
prognostic marker in patients with endometrial carcino-
ma6. Murray et al firstly described the MELF pattern of  
invasion in patients with endometrial adenocarcinoma7. 
Significantly higher rates of  myometrial invasion >50% 
were detected in patients with MELF compared to those 
with non-MELF8. Another study from Sanci et al report-
ed significant impact on overall survival (OS) n patients 
with MELF pattern compared with those with MELF (-)9.
Tripartite motif  containing 44 (TRIM44) has been 
demonstrated to be important in tumor metastasis and 
progression. High TRIM44 expression was associated 
with poor overall survival (OS) or disease-free survival 
(DFS) in EC patients10. High TRIM44 protein expression 
was significantly correlated with the FIGO stage, depth 
of  myometrial invasion, histological grade and lymph 
node metastasis10.
Myometrial invasion depth and lymph node involvement 
are also known to affect survival in endometrial carcino-
ma. In a large study carried out by Jones et al. five years’ 
survival rates of  patients with or without deep myometri-
al invasion were found as 60 % and 80 %, respectively11. 
Five years’ survival rates of  deep myometrial invasion in 
the literature were 71-88 % for grade I, 60-79 % for grade 
II and 32-65 % for grade III12,13. In the present study, 
the patients with myometrial invasion < 50 % was 88 % 
compared 67 % for the patients with myometrial inva-
sion > 50 % at 5 year PFS (p:0,0013). The 5-year OS 
rate was 96 % for patients with myometrial invasion < 50 
% versus 66 % for those with myometrial invasion > 50 
% (p<0,0001). We found a significant difference between 
PFS rates of  patients with and without myometrial inva-
sion. 
According to the prognostic parameters for endometri-
al carcinoma of  the uterine factors include histological 
type, histological grade and depth of  myometrial inva-
sion, lymphovascular invasion, presence of  atypical en-
dometrial hyperplasia, cervical involvement, DNA ploidy 
and S-shape fraction and hormone receptor status. The 
extra–uterine factors include positive peritoneal cytology, 
adnexal involvement, pelvic and para-aortic lymph node 
metastasis and peritoneal metastasis14,15. For a patient 
with endometrial cancer, the presence of  deep myometri-
al invasion is an important prognostic factor that strongly 
affects treatment planning and prognosis5. In this study, 
the prognostic value and relationship with clinicopatho-
logic parameters of  myometrial invasion were analyzed 
and compared.
The depth of  myometrial invasion is a highly important 
factor that can be used to predict nodal metastasis16. Be-
cause of  the higher prevalence of  lymph node metasta-
ses, patients with depth of  myometrial invasion are more 
likely to have a more extensive surgical lymph node as-
sessment than patients with absence of  myometrial in-
vasion17. In present study, we found pelvic lymph node 
and para-aortic lymph node metastasis, 9 %, 2.4 %, re-
spectively.
The patients with more than 50 % myometrial invasion 
on gross intraoperative examination of  the uterus appear 
to have a six- to seven-fold higher prevalence of  pelvic 
lymph node metastases, and advanced surgical stage com-
pared with women with less than 50% invasion, patients 
with deep myometrial invasion on gross examination 
should be considered for more aggressive surgical stag-
ing, including pelvic and para-aortic lymphadenectomy18. 
Invasion to more than half  of  the myometrium in pa-
tients were significantly associated with cervical exten-
sion, positive peritoneal fluid cytology, adnexal, LVSI and 
pelvic lymph node involvement in present study. How-
ever, there was no statistically significant association be-
tween omental involvement.
Previous studies showed that the tumor grade and the 
depth of  myometrial invasion, as well as LVSI, are useful 
predictors for the risk of  lymph node metastasis12,19. The 
incidence of  LVSI in patients with endometrial cancer 
is reported to be about 25 % when all the stages and tu-
mor grades are included20. In the present study, LVSI 
was positive in 32 patients (26.2 %), and this was similar 
to the results of  previous studies. 
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Patients with more than 50 % gross myometrial invasion 
have a 6.4-fold higher prevalence of  pelvic lymph node 
metastases and a 6.9-fold higher prevalence of  para-aor-
tic lymph node metastases than patients with less than 50 
% myometrial invasion21. Creasman et al., reported that 
the incidence of  para-aortic lymph nodal metastases in-
creased from 2 % in patients with no myometrial invasion 
to 21 % with deep myometrial invasion12. In our study, 
statistically significant associations were found between 
deep myometrial invasion and pelvic lymph node involve-
ment (OR: 11.2, p: 0,00029).
In the study of  Ayhan et al., there were extra-abdom-
inal metastases in 16 %; liver, spleen, or diaphragmatic 
spread in 24 %; small intestine involvement in 24 %; and 
large intestine involvement in 19% of  the patients22. The 
recurrence rate in our present study was 37.5 % (17 pa-
tients) excluded stage I. The recurrence site was vaginal 
in 11 patients (64.7 %), abdominal skin in 1 patient (5.8 
%), liver in 3 patients (17.6 %), and small intestine in 2 
patients (11.7 %). 
This study had several limitations. The sample size was 
relatively small and the study was retrospective in nature. 
Despite this limitation, the primary strength of  the study 
was that it was conducted in a single institution, where the 
pathological specimens are reviewed by experienced gy-
necologic pathologists. The size of  our study cohort was 
sufficient for analyzing the prognostic factors that were 
independently associated with DFS and OS.
Conclusion  
This single-center retrospective analysis confirms that 
myometrial invasion are important prognostic factors of  
progression-free survival and overall survival in patients 
diagnosed with endometrial cancer. 
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